| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Rodolfo Sacco | Q48874543 |
| Irene Bargellini | Q51359005 | ||
| Luca Giacomelli | Q56112038 | ||
| P2093 | author name string | Giuseppe Parisi | |
| Antonio Romano | |||
| Emanuele Tumino | |||
| Giampaolo Bresci | |||
| Graziana Federici | |||
| Marco Bertini | |||
| Salvatore Metrangolo | |||
| Sara Marceglia | |||
| Valeria Mismas | |||
| Luigi Giorgi | |||
| Carlo Bartolozzi | |||
| Manuel Tredici | |||
| Ambra Corti | |||
| Michele Piccinno | |||
| P2860 | cites work | Sorafenib in advanced hepatocellular carcinoma | Q27861075 |
| Hepatocellular carcinoma: epidemiology and molecular carcinogenesis | Q28306363 | ||
| Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial | Q29547903 | ||
| Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study | Q33691454 | ||
| Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma | Q34089023 | ||
| Hepatocellular Carcinoma: Consensus Recommendations of the National Cancer Institute Clinical Trials Planning Meeting | Q34131801 | ||
| Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis | Q34585175 | ||
| Gastrointestinal complications associated with hepatic arterial Yttrium-90 microsphere therapy. | Q34620919 | ||
| Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. | Q34622672 | ||
| Treatment Planning and Volumetric Response Assessment for Yttrium-90 Radioembolization: Semiautomated Determination of Liver Volume and Volume of Tumor Necrosis in Patients with Hepatic Malignancy | Q34681148 | ||
| Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes | Q35004090 | ||
| Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma | Q35085486 | ||
| Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations. | Q36573194 | ||
| Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma. | Q36673829 | ||
| Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept | Q36920698 | ||
| Multimodality imaging following 90Y radioembolization: a comprehensive review and pictorial essay. | Q37060054 | ||
| Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection. | Q37376714 | ||
| Modified RECIST (mRECIST) assessment for hepatocellular carcinoma | Q37696396 | ||
| Loco-regional treatment of hepatocellular carcinoma | Q37766546 | ||
| Radioembolization for hepatocellular carcinoma: a review of the evidence and treatment recommendations. | Q37771838 | ||
| Need, feasibility and convenience of dosimetric treatment planning in liver selective internal radiation therapy with (90)Y microspheres: the experience of the National Tumor Institute of Milan | Q37850992 | ||
| Transarterial chemoembolisation and radioembolisation for the treatment of primary liver cancer and secondary liver cancer: a review of the literature | Q38192781 | ||
| Yttrium-90 radioembolization of hepatic metastases from colorectal cancer | Q38239688 | ||
| In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization? | Q38984450 | ||
| Variant hepatic arterial anatomy revisited: digital subtraction angiography performed in 600 patients. | Q39609899 | ||
| Systematic evaluation of tumoral 99mTc-MAA uptake using SPECT and SPECT/CT in 502 patients before 90Y radioembolization | Q40255244 | ||
| Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation | Q42601023 | ||
| Prospective evaluation of the management of hepatocellular carcinoma in the elderly. | Q43495073 | ||
| Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial | Q44089673 | ||
| Is selective internal radioembolization safe and effective for patients with inoperable hepatocellular carcinoma and venous thrombosis? | Q44126350 | ||
| Yttrium 90 resin microspheres for the treatment of unresectable colorectal hepatic metastases after failure of multiple chemotherapy regimens: preliminary results | Q44426543 | ||
| Patient Selection and Activity Planning Guide for Selective Internal Radiotherapy With Yttrium-90 Resin Microspheres | Q44692003 | ||
| Prognostic utility of 90Y radioembolization dosimetry based on fusion 99mTc-macroaggregated albumin-99mTc-sulfur colloid SPECT. | Q45997151 | ||
| Biliary sequelae following radioembolization with Yttrium-90 microspheres | Q47746491 | ||
| Liver disease induced by radioembolization of liver tumors: description and possible risk factors | Q47925759 | ||
| Fibrosis, portal hypertension, and hepatic volume changes induced by intra-arterial radiotherapy with 90yttrium microspheres | Q47953062 | ||
| Management and prevention of adverse effects related to treatment of liver tumours with 90Y microspheres | Q50163011 | ||
| Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. | Q50535030 | ||
| Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. | Q51204089 | ||
| Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. | Q51642133 | ||
| MDCT necrosis quantification in the assessment of hepatocellular carcinoma response to yttrium 90 radioembolization therapy: comparison of two-dimensional and volumetric techniques. | Q53193242 | ||
| Incidence of radiation pneumonitis after hepatic intra-arterial radiotherapy with yttrium-90 microspheres assuming uniform lung distribution. | Q53391789 | ||
| Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC. | Q53525194 | ||
| Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results. | Q53671257 | ||
| Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis | Q56970979 | ||
| The intermediate hepatocellular carcinoma stage: Should treatment be expanded? | Q56988249 | ||
| Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: A phase 2 study | Q57763422 | ||
| Response to radioembolization with yttrium-90 resin microspheres may allow surgical treatment with curative intent and prolonged survival in previously unresectable hepatocellular carcinoma | Q58283601 | ||
| Radiation Lobectomy: Preliminary Findings of Hepatic Volumetric Response to Lobar Yttrium-90 Radioembolization | Q63198749 | ||
| Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres | Q63198750 | ||
| Radiation pneumonitis after selective internal radiation treatment with intraarterial 90Yttrium-microspheres for inoperable hepatic tumors | Q71821807 | ||
| Treatment of inoperable cancer of the liver by intra-arterial radioactive isotopes and chemotherapy | Q72218534 | ||
| Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer | Q73323825 | ||
| TREATMENT OF EXPERIMENTAL TUMORS; UTILIZATION OF RADIOACTIVE MICROSPHERES | Q76845800 | ||
| New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy | Q82877410 | ||
| A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization | Q84121312 | ||
| Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q84424049 | ||
| Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival | Q84634948 | ||
| P433 | issue | 21 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatocellular carcinoma | Q1148337 |
| P304 | page(s) | 6518-6525 | |
| P577 | publication date | 2015-06-01 | |
| P1433 | published in | World Journal of Gastroenterology | Q15708885 |
| P1476 | title | Transarterial radioembolization for hepatocellular carcinoma: An update and perspectives | |
| P478 | volume | 21 |
| Q47769035 | Absorbed dose kernel and self-shielding calculations for a novel radiopaque glass microsphere for transarterial radioembolization |
| Q37124697 | Consensus for Radiotherapy in Hepatocellular Carcinoma from The 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014): Current Practice and Future Clinical Trials. |
| Q47325384 | Cost-effectiveness analysis of treatments involving radioembolization in intermediate-stage hepatocellular carcinoma. |
| Q47748909 | Efficacy of 125I Versus Non-125I Combined with Transcatheter Arterial Chemoembolization for the Treatment of Unresectable Hepatocellular Carcinoma with Obstructive Jaundice |
| Q64087592 | Large hepatocellular carcinoma with local remnants after transarterial chemoembolization: treatment by sorafenib combined with radiofrequency ablation or sorafenib alone |
| Q41697309 | Microfluidic chip for isolation of viable circulating tumor cells of hepatocellular carcinoma for their culture and drug sensitivity assay |
| Q47156101 | Prognostic significance of XRCC4 expression in hepatocellular carcinoma |
| Q57055294 | Targeted and Immune-based Therapies for Hepatocellular Carcinoma |
| Q40099351 | Transarterial chemoembolization for the treatment of hepatocellular carcinoma: a review. |
| Q37474833 | Treating hepatocellular carcinoma with 90Y-bearing microspheres: a review |
| Q38652404 | Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres |
| Q36326015 | Yttrium-90 radioembolization for advanced inoperable hepatocellular carcinoma |
Search more.